Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Clinical Oncology

• Publication date

  2004-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2004.10.182PMID 14993230
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Cancer Statistics, 2003

  2003cited by this paper
• Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.

  2003cited by this paper
• Epidermal Growth Factor

  2002cited by this paper
• Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.

  2002cited by this paper
• Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.

  2001cited by this paper
• Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

  2000cited by this paper
• Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

  2000cited by this paper
• Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

  2000cited by this paper
• Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.

  1999cited by this paper
• Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.

  1999cited by this paper
• Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.

  1998cited by this paper
• Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody.

  1996cited by this paper
• Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145.

  1996cited by this paper
• Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin.

  1995cited by this paper
• Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.

  1995cited by this paper
• Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.

  1995cited by this paper
• Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.

  1993cited by this paper
• Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts.

  1993cited by this paper
• Ligand-induced activation of A431 cell epidermal growth factor receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly.

  1991cited by this paper
• Growth factors and cancer.

  1991cited by this paper
• Autocrine interaction between TGF alpha and the EGF-receptor: quantitative requirements for induction of the malignant phenotype.

  1989cited by this paper
• Growth factor receptor tyrosine kinases.

  1988cited by this paper
• Receptors for epidermal growth factor and other polypeptide mitogens.

  1987cited by this paper
• Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation.

  1986cited by this paper
• Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences

  1984cited by this paper
• Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity.

  1984cited by this paper
• Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies.

  1984cited by this paper
• Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors.

  1983cited by this paper
• EPIDERMAL GROWTH FACTOR *

  1982cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

  1934cited by this paper

• Advances in Targeted and Chemotherapeutic Strategies for Colorectal Cancer: Current Insights and Future Directions

  2025cites this paper
• Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA study

  2025cites this paper
• Targeted cancer treatment using a novel EGFR-specific Fc-fusion peptide based on GE11 peptide

  2025cites this paper
• The prognostic importance of the global immune-nutrition-information index (GINI) in patients with Ras wild type metastatic colorectal cancer

  2025cites this paper
• A masking clamp for conditional activation of therapeutic antibodies

  2025cites this paper
• BRG1 (SMARCA4) Status Dictates the Response to EGFR Inhibitors in Wild-Type EGFR Non-Small Cell Lung Cancer

  2025cites this paper
• Current and emerging concepts for systemic treatment of metastatic colorectal cancer

  2025cites this paper
• Jiedu Xiaozhen Granules for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Mediated Skin Toxicity: Protocol for a Randomized Controlled Trial

  2025cites this paper
• Cutaneous adverse effects of combination epidermal growth factor receptor inhibitor and immune checkpoint inhibitor cancer therapy

  2025cites this paper
• Comparison of genomic profiling of patient-matched primary colorectal and surgical resected distant metastatic (stage IV) colorectal carcinoma for drug actionability.

  2024cites this paper
• When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer

  2024cites this paper
• Nuclear miR-451a activates KDM7A and leads to cetuximab resistance in head and neck squamous cell carcinoma

  2024cites this paper
• Therapeutic proteins: developments, progress, challenges, and future perspectives

  2024cites this paper
• Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.

  2024cites this paper
• Incorporating Novel Technologies in Precision Oncology for Colorectal Cancer: Advancing Personalized Medicine

  2024cites this paper
• Loss-of-function mutation of REV1 (p.R704Q) mediates cetuximab primary resistance by activating autophagy in RAS-wild type metastatic colorectal cancer.

  2024cites this paper
• Colorectal cancer screening at age 45 years in Israel: Cost‐effectiveness and global implications

  2024cites this paper
• Delphi consensus for the third-line treatment of metastatic colorectal cancer

  2024cites this paper
• Advances in Personalized Oncology

  2024influential citation
• Bayesian meta‐analysis for evaluating treatment effectiveness in biomarker subgroups using trials of mixed patient populations

  2023cites this paper
• Multiple Protein Biomarkers and Different Treatment Strategies for Colorectal Carcinoma: A Comprehensive Prospective.

  2023cites this paper
• Receptor tyrosine kinases: biological functions and anticancer targeted therapy

  2023cites this paper
• A review on emerging targeted therapies for the management of metastatic colorectal cancers

  2023cites this paper
• Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications

  2023cites this paper
• New perspectives for targeting therapy in ALK-positive human cancers

  2023cites this paper
• Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor

  2023influential citation
• Predicting response to anti-EGFR antibody, cetuximab, therapy by monitoring receptor internalization and degradation.

  2023cites this paper
• A novel monoclonal antibody associated with glucoside kills gastric adenocarcinoma AGS cells based on glycosylation target

  2022cites this paper
• Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer

  2022cites this paper
• Current concepts of anti-EGFR targeting in metastatic colorectal cancer

  2022cites this paper
• The prognostic index of m7G-related genes in CRC correlates with immune infiltration

  2022cites this paper
• Armamentarium in Drug Delivery for Colorectal Cancer.

  2022cites this paper
• Prognostic Significance of HER3 Expression in Patients with Cervical Cancer

  2022cites this paper
• Improvement of Kiteplatin Efficacy by a Benzoato Pt(IV) Prodrug Suitable for Oral Administration

  2022cites this paper
• The HER family as therapeutic targets in colorectal cancer.

  2022cites this paper
• MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer.

  2022cites this paper
• Targeting KRAS mutant cancers: from druggable therapy to drug resistance

  2022cites this paper
• Current Targeted Therapy for Metastatic Colorectal Cancer

  2022cites this paper
• Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets

  2022cites this paper
• Relative quantitation of glycans in cetuximab using ultra-high-performance liquid chromatography-high-resolution mass spectrometry by Pronase E digestion.

  2022cites this paper
• The Impact of Long-Term Antibiotic Therapy of Cutaneous Adverse Reactions to EGFR Inhibitors in Colorectal Cancer Patients

  2021cites this paper
• Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors

  2021cites this paper
• CYTOPLASMIC-MEMBRANE EGFR PREDICTS EXPANDED RAS MUTATION STATUS IN COLORECTAL CARCINOMAS?

  2021cites this paper
• Review of chemotherapy‐associated paronychia

  2021cites this paper
• Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR‐targeting agents to treat head and neck squamous cell carcinoma

  2021cites this paper
• Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer.

  2021cites this paper
• Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review

  2021cites this paper
• EGFR Overexpression and Sequence Analysis of KRAS, BRAF, and EGFR Mutation Hot Spots in Canine Intestinal Adenocarcinoma

  2021cites this paper
• Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

  2021cites this paper
• Fatal anaphylaxis due to alpha-gal syndrome after initial cetuximab administration: The first forensic case report.

  2021cites this paper
• Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR

  2021cites this paper
• Efficacy and safety of topical benzoyl peroxide for prolonged acneiform eruptions induced by cetuximab and panitumumab: A multicenter, phase II trial

  2021cites this paper
• Proteomic profiling reveals a signature for optimizing prognostic prediction in Colon Cancer

  2021cites this paper
• Precision oncology in metastatic colorectal cancer — from biology to medicine

  2021cites this paper
• Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer

  2021cites this paper
• Drug delivery, biodistribution and anti-EGFR activity: theragnostic nanoparticles for simultaneous in vivo delivery of tyrosine kinase inhibitors and kinase activity biosensors

  2021cites this paper
• Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives

  2021cites this paper
• The Adroitness of Andrographolide as a Natural Weapon Against Colorectal Cancer

  2021cites this paper
• Network Meta-analysis of First-Line Systemic Treatment for Patients With Metastatic Colorectal Cancer

  2021cites this paper
• Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial

  2021cites this paper
• High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms

  2021cites this paper
• Therapeutic Proteins: Production and Delivery

  2021cites this paper
• The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer

  2021cites this paper
• Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer

  2020cites this paper
• Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.

  2020cites this paper
• Effects of propofol on colon cancer metastasis through STAT3/HOTAIR axis by activating WIF‐1 and suppressing Wnt pathway

  2020cites this paper
• Colorectal cancer (CRC) as a multifactorial disease and its causal correlations with multiple signaling pathways

  2020cites this paper
• Retrospective analysis of the efficacy and safety of cabazitaxel treatment in castration-resistant prostate cancer after docetaxel failure

  2020cites this paper
• Epidermal growth factor receptor (EGFR) involvement in epithelial‐derived cancers and its current antibody‐based immunotherapies

  2020cites this paper
• Systemic therapy as First-Line Treatment for Patients with Metastatic Colorectal Cancer: A Systematic Review and Network meta-analysis of Randomized Clinical Trials

  2020cites this paper
• Sticking to the Problem: Engineering Adhesion in Molecular Endoscopic Imaging

  2020cites this paper
• Neurological Toxicities of Immunotherapy

  2020cites this paper
• A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR

  2020cites this paper
• The role of IgE specific for galactose-α-1,3-galactose in predicting cetuximab induced hypersensitivity reaction: a systematic review and a diagnostic meta-analysis

  2020cites this paper
• Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine

  2020cites this paper
• Potentially Resectable mCRC-treated with Cetuximab Combined with Chemotherapy.

  2020cites this paper
• Blood-based RAS mutation testing: concordance with tissue-based RAS testing and mutational changes on progression.

  2020cites this paper
• Nuances to precision dosing strategies of targeted cancer medicines

  2020cites this paper
• Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate

  2020cites this paper
• Trends in Primary Surgical Resection and Chemotherapy for Metastatic Colorectal Cancer, 2000-2016

  2020cites this paper
• BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy

  2020cites this paper
• Intracellular Signaling

  2020cites this paper
• Systemic Steroid Treatment for Imatinib-Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study.

  2020cites this paper
• Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion.

  2020cites this paper
• Successful rechallenge with cetuximab after an infusion related reaction to panitumumab in a patient with locally advanced rectal cancer

  2020cites this paper
• Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?

  2020cites this paper
• ZEB2-AS1 regulates the expression of TAB3 and promotes the development of colon cancer by adsorbing microRNA-188.

  2020cites this paper
• Clinical Study Protocol

  2020cites this paper
• Short bowel syndrome and severe skin toxicity as a complication of FOLFOX chemotherapy with panitumumab in a patient with colorectal cancer — a case report

  2020cites this paper
• Cost Effectiveness Analysis Evaluating Real-Time Characterization of Diminutive Colorectal Polyp Histology using Narrow Band Imaging (NBI)SHORT TITLE: Cost Effectiveness of Narrow Band Imaging Optical Diagnosis of Diminutive Colorectal Polyps

  2020cites this paper
• EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer.

  2020cites this paper
• Grade 3 infusion-related reaction because of cetuximab administered with 5-fluorouracil and cisplatin chemotherapy for a recurrent and metastatic head and neck cancer patient who received chlorpheniramine 5 mg, dexamethasone 13.2 mg, and aprepitant 125 mg premedication

  2020cites this paper
• Therapeutics Targeting Mutant KRAS.

  2020cites this paper
• Growth-inhibitory effects of TGFαL3-SEB chimeric protein on colon cancer cell line.

  2019cites this paper
• Association between Subjective Evaluation of Skin Toxicities and Quality of Life in Patients with Lung Cancer Undergoing Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Pilot Study for Developing Skin Toxicity Assessment

  2019cites this paper
• ROR1 Expression and Its Functional Significance in Hepatocellular Carcinoma Cells

  2019cites this paper
• Small molecule tyrosine kinase inhibitors and pancreatic cancer-Trials and troubles.

  2019cites this paper
• Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR

  2019cites this paper
• Standardized Pathology Report for Colorectal Cancer, 2nd Edition

  2019influential citation
• Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial

  2019cites this paper